Annual report pursuant to Section 13 and 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.21.1
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Noncontrolling Interest [Line Items]    
NCI equity share $ 153,120 $ 108,017
Net loss attributable to non-controlling interests (56,459) (61,700)
Non-controlling interests in consolidated entities 96,661 46,317
Acquisition Corp VIII [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share (7)  
Net loss attributable to non-controlling interests (27)  
Non-controlling interests in consolidated entities $ (34)  
Non-controlling ownership 10.00%  
Aevitas [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (2,370) (1,249)
Net loss attributable to non-controlling interests (823) (694)
Non-controlling interests in consolidated entities $ (3,193) $ (1,943)
Non-controlling ownership 39.00% 35.80%
Avenue [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 5,800 $ 24,269
Net loss attributable to non-controlling interests (3,974) (19,011)
Non-controlling interests in consolidated entities $ 1,826 $ 5,258
Non-controlling ownership 77.40% 77.30%
Baergic [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (1,662) $ 23
Net loss attributable to non-controlling interests (97) (1,162)
Non-controlling interests in consolidated entities $ (1,759) $ (1,139)
Non-controlling ownership 39.50% 33.00%
Cellvation [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (1,089) $ (732)
Net loss attributable to non-controlling interests (182) (158)
Non-controlling interests in consolidated entities $ (1,271) $ (890)
Non-controlling ownership 22.10% 20.60%
Checkpoint [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 41,704 $ 29,389
Net loss attributable to non-controlling interests (13,265) (14,687)
Non-controlling interests in consolidated entities $ 28,439 $ 14,702
Non-controlling ownership 80.40% 78.00%
Coronado SO [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (290) $ (290)
Net loss attributable to non-controlling interests 0 0
Non-controlling interests in consolidated entities $ (290) $ (290)
Non-controlling ownership 13.00% 13.00%
Cyprium [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 567 $ (320)
Net loss attributable to non-controlling interests (1,478) (99)
Non-controlling interests in consolidated entities $ (911) $ (419)
Non-controlling ownership 30.50% 10.60%
Helocyte [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (4,986) $ (4,322)
Net loss attributable to non-controlling interests (259) (402)
Non-controlling interests in consolidated entities $ (5,245) $ (4,724)
Non-controlling ownership 18.80% 19.30%
JMC [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 138 $ (211)
Net loss attributable to non-controlling interests 491 325
Non-controlling interests in consolidated entities $ 629 $ 114
Non-controlling ownership 7.10% 6.90%
Mustang [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 116,060 $ 62,025
Net loss attributable to non-controlling interests (36,429) (25,727)
Non-controlling interests in consolidated entities $ 79,631 $ 36,298
Non-controlling ownership 80.90% 70.30%
Oncogenuity [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (82)  
Net loss attributable to non-controlling interests (376)  
Non-controlling interests in consolidated entities $ (458)  
Non-controlling ownership 25.30%  
Tamid [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (663) $ (565)
Net loss attributable to non-controlling interests (40) (85)
Non-controlling interests in consolidated entities $ (703) $ (650)
Non-controlling ownership 22.80% 22.80%